Antigen-triggered interferon-gamma and interleukin-10 pattern in cured mucosal leishmaniasis patients is shaped during the active phase of disease

Imagem de Miniatura
Arquivos
art_NOGUEIRA_Antigentriggered_interferongamma_and_interleukin10_pattern_in_cured_mucosal_2014.PDF (617.39 KB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2014
Editora
WILEY-BLACKWELL
DOI
Indexadores
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Autores
NOGUEIRA, R. S.
GOMES-SILVA, A.
BITTAR, R. C.
MENDONCA, D. Silva
MATTOS, M. da Silva
OLIVEIRA-NETO, M. P.
COUTINHO, S. G.
DA-CRUZ, A. M.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, v.177, n.3, p.679-686, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
An exacerbated type 1 response to leishmanial antigens is the basis of tissue destruction observed in mucosal leishmaniasis (ML). After therapy, a persistent production of high levels of inflammatory cytokines can confer a poor prognosis. Herein we investigated whether the clinical conditions defined during the active phase of ML affect the magnitude of long-term anti-Leishmania immune response. Twenty clinically cured ML cases were studied. Peripheral blood mononuclear cells (PBMC) were cultured with L. braziliensis antigens (Lb-Ag), Toxoplasma gondii antigens (Tg-Ag), concanavalin-A (Con-A) or medium alone, and the lymphocyte proliferative response and cytokine secretion were quantified. Medical records were reviewed for Montenegro skin test (MST) during diagnosis, duration of ML disease or time elapsed after clinical cure. The duration of disease was correlated positively with MST (r = 0.61). Lb-Ag induced interferon (IFN)-gamma was correlated positively with duration of illness (r = 0 69) as well as the frequency of secreting cells [enzyme-linked immunospot (ELISPOT)] assay. No association was observed for Tg-Ag or Con-A. Disease duration was correlated negatively with interleukin (IL)-10 production (r = -0.76). Moreover, a negative correlation between length of time after clinical cure and TNF levels (r = -0.94) or the IFN-gamma : IL-10 ratio (r = -0.89) were also seen. We suggest that the magnitude of the IFN-gamma inflammatory response triggered by ML can be driven by the time of leishmanial antigens exposition during the active phase of the disease. This pattern could persist even long-term after cure. However, despite IFN-gamma levels, the decrease of the TNF and IFN-gamma : IL-10 ratio reflects the control of proinflammatory responses achieved by cure of ML, possibly preventing disease relapses.
Palavras-chave
clinical cure, duration of illness, interferon-gamma, interleukin-10, mucosal leishmaniasis
URI
https://observatorio.fm.usp.br/handle/OPI/8462
Referências
  1. Amato VS, 2003, ACTA TROP, V85, P39, DOI 10.1016/S0001-706X(02)00260-7
  2. Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
  3. Bacellar O, 2009, J INFECT DIS, V200, P75, DOI 10.1086/599380
  4. Brazil: Ministerio da Saude Secretaria de Vigilancia em Saude, 2010, NORMAS MANUAIS TEC A
  5. Brodskyn CI, 1997, J IMMUNOL, V159, P4467
  6. CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
  7. CARVALHO EM, 1985, J IMMUNOL, V135, P4144
  8. Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
  9. Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
  10. CONCEICAOSILVA F, 1990, CLIN EXP IMMUNOL, V79, P221
  11. DaCruz AM, 1996, MEM I OSWALDO CRUZ, V91, P225, DOI 10.1590/S0074-02761996000200019
  12. Da-Cruz AM, 2005, BRIT J DERMATOL, V153, P537, DOI 10.1111/j.1365-2133.2005.06647.x
  13. Da-Cruz AM, 2002, CLIN DIAGN LAB IMMUN, V9, P251, DOI 10.1128/CDLI.9.2.251-256.2002
  14. Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
  15. FRANKE ED, 1990, ANN INTERN MED, V113, P934
  16. Gaze ST, 2006, SCAND J IMMUNOL, V63, P70, DOI 10.1111/j.1365-3083.2005.01707.x
  17. Gomes-Silva A, 2007, CLIN EXP IMMUNOL, V149, P440, DOI 10.1111/j.1365-2249.2007.03436.x
  18. JONES TC, 1987, J INFECT DIS, V156, P73
  19. Lee JS, 2002, CLIN EXP IMMUNOL, V128, P516, DOI 10.1046/j.1365-2249.2002.01858.x
  20. MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
  21. Matos GI, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-33
  22. Mattos M. S., 2006, Revista da Sociedade Brasileira de Medicina Tropical, V39, P94
  23. NETTO EM, 1990, T ROY SOC TROP MED H, V84, P367, DOI 10.1016/0035-9203(90)90321-5
  24. Oliveira MR, 1995, REV SOC BRAS MED TRO, V28, P325
  25. Pessoa SB, 1948, LEISHMANIOSE TEGUMEN
  26. Pompeu MML, 2001, INFECT IMMUN, V69, P7453, DOI 10.1128/IAI.69.12.7453-7460.2001
  27. Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
  28. Tuon FF, 2008, CLIN IMMUNOL, V128, P442, DOI 10.1016/j.clim.2008.05.007
  29. Yoshimoto T, 1998, J IMMUNOL, V161, P3400
  30. ZAJTCHUK JT, 1989, LARYNGOSCOPE, V99, P925

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/46